New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
08:11 EDTINFIInfinity Pharmaceuticals sees 2013 net loss $115M-$125M
Consensus for FY13 EPS is ($3.04). The company said it entered 2013 with approximately $327M in cash and investments. Infinity expects operating expenses for 2013 to range from $115M-$125M, net loss for 2013 to range from $115M-$125M and expects to end 2013 with a year-end cash and investments balance ranging from $210M-$220M. Based on its current operating plan and exclusive of any business development activities, Infinity’s financial foundation provides a cash runway into 2015, the company said.
News For INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:04 EDTINFIInfinity Pharmaceuticals coverage resumed with a Hold at Stifel
October 16, 2014
07:41 EDTINFIInfinity reports duvelisib Phase 2a primary endpoint not met
Infinity Pharmaceuticals announced encouraging topline data from its Phase 2a exploratory study of duvelisib, or IPI-145. Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement was observed in the late-phase asthmatic response FEV1 among patients who received duvelisib administered at the highest dose tested, 25 mg twice daily for five days, however the primary endpoint of the study was not met as it did not reach statistical significance. Multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance and were associated with changes in key cytokines and chemokines involved in the asthmatic response. Taken together, these data demonstrate early proof-of-activity in this allergen challenge study. Infinity expects to present the final data in a peer-reviewed setting after all analyses are complete. In addition, the company anticipates determining its next steps for development of PI3K-delta,gamma inhibitors in inflammation after evaluating the results from the ASPIRA study in rheumatoid arthritis, which are expected by the end of 2014.
October 13, 2014
13:05 EDTINFIInfinity Pharmaceuticals management to meet with ISI Group
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use